DEA Proposes Registration Fee Increases To Fund Diversion Control Program
This article was originally published in The Tan Sheet
Executive Summary
Non-retail distributors of pseudoephedrine, phenylpropanolamine and combination ephedrine products would be required to pay the full amount of Drug Enforcement Administration registration fees, under a proposed rule published in the Federal Register Nov. 16
You may also be interested in...
OTC Bronchodilators Face Near Extinction Under FDA Proposal – Trade Group
FDA's proposal to reclassify OTC ephedrine combination products as Category II would effectively remove ephedrine bronchodilators from the consumer marketplace, according to comments recently submitted to the agency by an industry trade group
OTC Bronchodilators Face Near Extinction Under FDA Proposal – Trade Group
FDA's proposal to reclassify OTC ephedrine combination products as Category II would effectively remove ephedrine bronchodilators from the consumer marketplace, according to comments recently submitted to the agency by an industry trade group
OTC Bronchodilators Face Near Extinction Under FDA Proposal – Trade Group
FDA's proposal to reclassify OTC ephedrine combination products as Category II would effectively remove ephedrine bronchodilators from the consumer marketplace, according to comments recently submitted to the agency by an industry trade group